Showing results (231-240 of 9,974) with videos related to

Sort By:
Pageof 998
Leukemia & Lymphoma|January 29, 2021
A phase-1 trial of linsitinib (OSI-906) in combination with bortezomib and dexamethasone for the treatment of relapsed/refractory multiple myelomaSahar Khan, Richard LeBlanc, Martin Gyger, et al.
Leukemia & Lymphoma|July 30, 2019
A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemiaLeslie A Andritsos, John C Byrd, Peter Cheverton, et al.
Leukemia & Lymphoma|January 3, 2022
Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed/refractory large B-cell lymphomas: an indirect treatment comparisonStephen J Schuster, Jie Zhang, Hongbo Yang, et al.
Leukemia & Lymphoma|January 6, 2022
Second primary malignancy risk after Hodgkin lymphoma treatment among HIV-uninfected and HIV-infected survivorsRenata Abrahão, Ann M Brunson, Justine M Kahn, et al.
Leukemia & Lymphoma|January 6, 2022
Telehealth access among hematology patients during the COVID-19 pandemic in Australia: a cross-sectional surveyNienke Zomerdijk, Michelle I Jongenelis, Jane Turner, et al.
Leukemia & Lymphoma|December 6, 2021
Allogeneic hematopoietic stem cell transplantation in T-cell lymphoma: a Meta-AnalysisVijendra Singh, Seongho Kim, Abhinav Deol, et al.
Leukemia & Lymphoma|December 7, 2021
SOCS-2 gene expression at diagnosis does not predict for outcome of chronic myeloid leukemia patients on imatinib treatmentDamla Buket Egeli, Benjamin Hanfstein, Michael Lauseker, et al.
Leukemia & Lymphoma|December 8, 2021
Inhibition of pyrimidine biosynthesis by strobilurin derivatives induces differentiation of acute myeloid leukemia cellsXing Shen, Lu Zhang, Shuang Xing, et al.
Leukemia & Lymphoma|December 13, 2021
Long term survival in multiple myeloma: a single institution experience in underprivileged circumstancesLorena Bojalil-Alvarez, Morie A Gertz, Elizabeth Garcia-Villaseñor, et al.
Leukemia & Lymphoma|January 11, 2022
Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studiesJan A Burger, Tadeusz Robak, Fatih Demirkan, et al.
Pageof 998